LOW HIV-1 RESISTANCE IN SUBJECTS USING DARUNAVIR ONCE-DAILY REGIMENS ACROSS STUDIES
Across Phase 2/3 studies evaluating once-daily (QD) darunavir (DRV) regimens, treatment-naïve (TN) or treatment experienced (TE), including virologically suppressed, HIV-1–infected subjects were treated for 48-192 wk. We summarize treatment-emergent drug resistance-associated mutations (RAMs) for subjects receiving DRV QD dosing from 7 studies. Sponsored studies with available genotypes were assessed. TN studies: ARTEMIS (N=343; DRV+ritonavir [r]+emtricitabine…